Greg GardellaView Public Profile
Mr. Greg H. Gardella is the Managing Principal of Gardella Grace and spearheads the firm’s Post-Grant Proceedings practice. Recognized as a premier national expert in the field of post-grant proceedings, he has been honored as one of the Best Lawyers in America for multiple consecutive years and has likewise received various awards and recognition from U.S. News & World Report, Chambers & Partners, Managing IP Magazine, Intellectual Asset Management (IAM), Super Lawyers and Who’s Who Legal. He has been repeatedly named as one of the nation’s top post-grant practitioners by IAM, which previously reported that “the ‘phenomenal’ Greg H. Gardella is ‘extremely experienced in the post-grant space and a dynamic all-round patent consultant’” and noted that his “former big-ticket patent litigation experience has served him well in contested reexamination proceedings, of which he is regarded a master.” Mr. Gardella is one of only a handful of U.S. patent attorneys to have earned spots on both IAM Patent 1000 Global Leaders and IAM Strategy 300 Global Leaders.
Mr. Gardella successfully defended the famous TiVo DVR patent, which thereafter generated well over $1 billion in licensing revenue. Mr. Gardella also successfully defended before the Patent Trial and Appeal Board four patents covering aseptic packaging technologies that are used to process about 2 billion bottles per year. On the challenger side, Mr. Gardella prevailed for St. Jude Medical in nine post-grant proceedings targeting numerous Medtronic patents that purportedly covered the billion-dollar denervation industry. In those cases, every challenged claim was finally adjudicated to be invalid on multiple grounds.
Mr. Gardella was also the editor of a treatise on post-grant practice entitled “Post-Grant Proceedings Before the Patent Trial and Appeal Board,” published by Practicing Law Institute. He has frequently lectured on post-grant proceedings and strategies for effective execution of concurrent litigation, post-grant proceedings and patent prosecution.
Mr. Gardella has broad technical aptitude arising from his dual degrees in electrical and mechanical engineering and from years of representations involving DNA detection and sequencing, genetic diagnosis and screening, organic chemistry, immunochemistry, pharmaceutical and other biotechnology innovations. Mr. Gardella has deep familiarity with the technologies underlying most medical devices, polymerization processes, genetic sequencing techniques, semiconductor fabrication and device structure, computer architecture, wireless telecommunications, network data communication, software ranging from microcode to application layer, signal processing, VLSI design, micro-structured films, and industrial equipment.
Sessions with Greg Gardella
03:00 PM EST
January 25, 2022
AIA trials were designed to replace patent reexamination. So why are reexamination filings on the uptick? And what can patent owners gain from patent reissue and reexamination that may help stave off future PTAB attacks, or otherwise rehabilitate a vulnerable portfolio? CLE Materials Unified Report: Reexaminations Double; Samsung, Apple and Google Dominate PTAB Filings Reexam After Failed IPR? Federal Circuit…